Treatment outcomes and prognostic factors of feline splenic mast cell tumors: A multi‐institutional retrospective study of 64 cases

Publisher： John Wiley & Sons Inc

E-ISSN： 1476-5829|16|1|20-27

ISSN： 1476-5810

Source： VETERINARY AND COMPARATIVE ONCOLOGY, Vol.16, Iss.1, 2018-03, pp. : 20-27

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Background

Mast cell tumors (MCT) are common splenic tumors in cats, but there is limited information on treatment outcomes of cats with this disease.

Materials and methods

This retrospective study evaluated treatment outcomes in 64 cats with splenic MCT. Cats were categorized into the following treatment groups: splenectomy (A, n = 20); splenectomy with chemotherapy (B, n = 20); chemotherapy alone (C, n = 15); or supportive care (D, n = 9).

Results

Median tumor specific survival (MTSS) was: 856, 853, 244, 365 days for groups A, B, C, and D, respectively. The MTSS was not significantly different between the 4 groups. However, comparing cats that had splenectomy (A and B) versus those that did not (C and D), the MTSS was 856 and 342 days, respectively (p=0.008). None of the prognostic factors analyzed significantly influenced survival.

Conclusion

Splenectomy (+/‐ chemotherapy) significantly prolongs survival in cats with mast cell tumors. The role of chemotherapy remains unknown.